QALY, quality-adjusted life year; EUR, 2013 Euros; ICER, incremental cost-effectiveness ratio * ICERs are presented in EUR per QALY gained; RS, Recurrence Score. Summary of one-way sensitivity analysi
BackgroundThe effectiveness of Sacituzumab Govitecan (SG) for metastatic triple-negative breast cancer (mTNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on mTNBC from the Chin
Background and objectivesThe estimation of a cost- Effectiveness (CE) threshold from the perspective of those who have experienced a life-threatening disease can provide empirical evidence for health
